Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 77 results for lower urinary tract symptoms

  1. ADXBLADDER for detecting bladder cancer (MIB180)

    NICE has developed a medtech innovation briefing (MIB) on ADXBLADDER for detecting bladder cancer .

    Medtech innovation briefing
    Published
    12 April 2019

  2. NICE encourages further research and publication of results from consecutive case series of patients having this procedure. Details of patient selection should be clearly documented. Reported outcomes should include the effects of the procedure on symptoms and quality of life, the duration of benefits, and the need for further procedures. All complications should be reported. NICE may review this procedure in the light of longer-term outcomes.

    documented. Reported outcomes should include the effects of the procedure on symptoms and quality of life, the duration of benefits, and...

    Research recommendation
    Published
    9 June 2015

  3. URO17 for detecting bladder cancer (MIB250)

    NICE has developed a medtech innovation briefing (MIB) on URO17 for detecting bladder cancer .

    Medtech innovation briefing
    Published
    4 February 2021

  4. Transcutaneous electrical neuromuscular stimulation for urinary incontinence (IPG735)

    Evidence-based recommendations on transcutaneous electrical neuromuscular stimulation for urinary incontinence in adults. This involves stimulating nerves and muscles in the pelvic floor to strengthen the muscles and reduce urine leaks.

    Interventional procedures guidance
    Published
    24 August 2022
    View recommendations

    Sections for IPG735

  5. Focal therapy using high-intensity focused ultrasound for localised prostate cancer (IPG756)

    Evidence-based recommendations on focal therapy using high-intensity focused ultrasound for localised prostate cancer. This involves using high-intensity focused ultrasound to heat up and destroy only the areas of the prostate with cancer (focal therapy). The aim is to destroy the cancer while reducing damage to healthy prostate tissue.

    Interventional procedures guidance
    Published
    5 April 2023
    View recommendations

    Sections for IPG756

  6. Urinary tract infection (recurrent): antimicrobial prescribing (NG112)

    This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Last updated
    12 December 2024
    View recommendations

    Sections for NG112

  7. Lower urinary tract symptoms in men, trans and non-binary people with a prostate: assessment and management (update)

    Discontinued Reference number: GID-NG10300

    NICE guideline
    Discontinued

  8. Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 June 2016

  9. Further evidence to address uncertainties about the relative clinical and cost effectiveness of UroLift compared with Rezum, especially in the NHS, would be welcome. This should include: • exploring long-term clinical outcomes and reintervention rates after UroLift • assessing the suitability of UroLift for prostates larger than 80 ml and for those with an obstructive median lobe.

    details Comes from guidance UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia Number MTG58

    Research recommendation
    Published
    10 August 2021

  10. BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume (MIB50)

    NICE has developed a medtech innovation briefing (MIB) on the BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume

    Medtech innovation briefing
    Published
    22 January 2016

  11. Pneumonia: diagnosis and management (NG250)

    This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected gestational age), children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

    NICE guideline
    Published
    2 September 2025
    View recommendations

    Sections for NG250

  12. Urinary tract infection (lower). Patient decision aid on cystitis: taking an antibiotic

    getting into your bladder. Cystitis is also called lower urinary tract infection or UTI. Sometimes symptoms get better by...

  13. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

    Technology appraisal guidance
    Published
    26 June 2013
    View recommendations

    Sections for TA290

  14. Infracoccygeal sacropexy using mesh to repair uterine prolapse (IPG582)

    Evidence-based recommendations on infracoccygeal sacropexy using mesh to repair uterine prolapse in women. This involves attaching mesh from the buttocks to the top of the vagina to hold the uterus in place.

    Interventional procedures guidance
    Published
    28 June 2017
    View recommendations

    Sections for IPG582

  15. Urinary tract infection in children and young people (QS36)

    This quality standard covers diagnosing and managing urinary tract infection in infants, children and young people (under 16). It includes new and recurrent infections of the upper or lower urinary tract. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    27 July 2022
    View quality statements

    Sections for QS36